Marco Uboldi, Alice Melocchi, Saliha Moutaharrik, Luca Palugan, Matteo Cerea, Anastasia Foppoli, Alessandra Maroni, Andrea Gazzaniga, Lucia Zema
Targeting the release of drugs in specific sites of the upper GI tract would meet local therapeutic goals, improve the bioavailability of specific drugs and help overcoming compliance-related limitations, especially in chronic illnesses of great social/economic impact and involving polytherapies (e.g. Parkinson's and Alzeimer's disease, tubercolosis, malaria, HIV, HCV). It has been traditionally pursued using gastroretentive (GR) systems, i.e. low-density, high-density, magnetic, adhesive and expandable devices...
June 8, 2022: Journal of Controlled Release